MedTrace Logo

Sarcopenia in the Acute Stroke

NCT06603701 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-12-04

No results posted yet for this study

Summary

Regardless of the cause of immobilization, within days or weeks there is rapidly a decrease in strength and muscle mass, which can lead to sarcopenia. In severe strokes, immobilization and neurologic damage may be added to promote sarcopenia. Several studies in Asian populations confirm rapid increases in sarcopenia rates after stroke, but there are only rare data in Western populations. The aim of this work is to monitor during the first 10 days after a severe stroke leading to a reduction in ambulation, the evolution of muscle strength (studied in dynamometry), body composition (studied by impedance measurement) and sarcopenia rates. Investigators will also look for factors that predict the occurrence of this sarcopenia (such as sex, age, initial deficiency, stroke volume, swallowing disorders, etc.).

Conditions

  • Stroke, Acute

Interventions

DIAGNOSTIC_TEST

Bioimpedancemetry

2\. Bioimpedancemetry at T1, T2, T3 ; the measurement will be 1. Squeletic mass (total and for each of the 4 limbs) 2. Angle phase (total and for each of the 4 limbs)

OTHER

Dynamometry

Dynamometry will be performed to assess the strength of each upper limb (deficient and non deficient) at T1, T2, T3

Sponsors & Collaborators

  • Centre Hospitalier Régional d'Orléans

    lead OTHER

Principal Investigators

  • Canan OZSANCAK, PH · CHU Orléans

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-28
Primary Completion
2024-08-06
Completion
2024-08-06

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06603701 on ClinicalTrials.gov